Kura Oncology (KURA) Stock Forecast, Price & News

Kura Oncology (NASDAQ:KURA) Frequently Asked Questions

Is Kura Oncology a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Kura Oncology stock.
View analyst ratings for Kura Oncology or view top-rated stocks.

When is Kura Oncology's next earnings date?

Kura Oncology is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Kura Oncology.

How were Kura Oncology's earnings last quarter?

Kura Oncology, Inc. (NASDAQ:KURA) announced its quarterly earnings results on Wednesday, May, 4th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.03. During the same quarter in the prior year, the business posted ($0.46) EPS.
View Kura Oncology's earnings history.

What price target have analysts set for KURA?

6 brokerages have issued 1 year target prices for Kura Oncology's shares. Their forecasts range from $26.00 to $80.00. On average, they anticipate Kura Oncology's share price to reach $38.00 in the next twelve months. This suggests a possible upside of 201.8% from the stock's current price.
View analysts' price targets for Kura Oncology or view top-rated stocks among Wall Street analysts.

Who are Kura Oncology's key executives?

Kura Oncology's management team includes the following people:

• Dr. Troy Edward Wilson J.D., Ph.D., Chairman, CEO, Pres & Principal Financial Officer (Age 53, Pay $1.11M)
• Ms. Kathleen Ford, Chief Operating Officer (Age 75, Pay $683.4k)
• Dr. Marc Grasso M.D., Advisor (Age 48, Pay $715.95k)
• Ms. Kirsten Flowers, Chief Commercial Officer (Age 46, Pay $661.25k)
• Dr. Stephen Dale M.D., Chief Medical Officer (Age 50, Pay $398.93k)
• Mr. Thomas Doyle, Principal Accounting Officer & Sr. VP of Fin. and Accounting (Age 51)
• Mr. Pete De Spain, Sr. VP of Investor Relations & Corp. Communications
• Mr. James E. Basta J.D., Esq., Chief Compliance Officer & Corp. Sec. (Age 56)
• Ms. Teresa Brophy Bair Esq., J.D., Chief Legal Officer & Corp. Sec. (Age 51)
• Dr. Roger Bakale Ph.D., VP and Head of CMC, Clinical & Commercial Manufacturing

Who are some of Kura Oncology's key competitors?

Some companies that are related to Kura Oncology include Karuna Therapeutics (KRTX), Pacira BioSciences (PCRX), ACADIA Pharmaceuticals (ACAD), Indivior (INVVY), Prestige Consumer Healthcare (PBH), Insmed (INSM), Arvinas (ARVN), PTC Therapeutics (PTCT), Harmony Biosciences (HRMY), Amicus Therapeutics (FOLD), Corcept Therapeutics (CORT), EQRx (EQRX), OPKO Health (OPK), Sage Therapeutics (SAGE) and Turning Point Therapeutics (TPTX).
View all of KURA's competitors.

What other stocks do shareholders of Kura Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD).

What is Kura Oncology's stock symbol?

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

Who are Kura Oncology's major shareholders?

Kura Oncology's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.42%), Deerfield Management Company L.P. Series C (6.63%), Suvretta Capital Management LLC (5.84%), Deep Track Capital LP (5.12%), Vanguard Group Inc. (5.00%) and State Street Corp (4.95%). Company insiders that own Kura Oncology stock include Kathleen Ford, Marc Grasso and Troy Edward Wilson.
View institutional ownership trends for Kura Oncology.

Which institutional investors are selling Kura Oncology stock?

KURA stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Wellington Management Group LLP, Candriam Luxembourg S.C.A., BlackRock Inc., Citigroup Inc., State Street Corp, SG Americas Securities LLC, and AlphaCrest Capital Management LLC.
View insider buying and selling activity for Kura Oncology or view top insider-selling stocks.

Which institutional investors are buying Kura Oncology stock?

KURA stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Deerfield Management Company L.P. Series C, Deep Track Capital LP, Aaron Wealth Advisors LLC, Eventide Asset Management LLC, Verition Fund Management LLC, Affinity Asset Advisors LLC, and Suvretta Capital Management LLC.
View insider buying and selling activity for Kura Oncology or or view top insider-buying stocks.

How do I buy shares of Kura Oncology?

Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kura Oncology's stock price today?

One share of KURA stock can currently be purchased for approximately $12.59.

How much money does Kura Oncology make?

Kura Oncology has a market capitalization of $839.00 million. The company earns $-130.47 million in net income (profit) each year or ($1.990010) on an earnings per share basis.

How many employees does Kura Oncology have?

Kura Oncology employs 121 workers across the globe.

What is Kura Oncology's official website?

The official website for Kura Oncology is www.kuraoncology.com.

How can I contact Kura Oncology?

Kura Oncology's mailing address is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. The company can be reached via phone at (858) 500-8800 or via email at [email protected].